Skip to main content

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it has closed a Series C financing raising gross proceeds of approximately $40 million. The financing was led by a new investor along with strong support from current investors, including Venture Investors Health Fund, Arboretum Ventures and Falcon Vision, an ophthalmology investment platform supported by KKR.

Read Article